Contineum Therapeutics (CTNM) Tax Provisions (2023 - 2024)
Contineum Therapeutics (CTNM) posted quarterly Tax Provisions of -$8.9 million for Q4 2024, down 307.84% year-over-year from $4.3 million in Q1 2024, and down 307.84% quarter-over-quarter from $4.3 million in Q4 2023.
Powered by 
Analysis
Contineum Therapeutics (CTNM) Tax Provisions (2023 - 2024) Analysis & Trends
Contineum Therapeutics' Tax Provisions history runs 2 years deep, the most recent figure standing at -$8.9 million for Q4 2024.
- In Q4 2024, Tax Provisions fell 307.84% year-over-year to -$8.9 million; the TTM figure through Dec 2024 stood at -$8.9 million (down 281.85% YoY), while the FY2024 annual figure was -$8.9 million, down 281.85% from the prior year.
- Tax Provisions for Q4 2024 stood at -$8.9 million, down from $4.3 million in the prior quarter.
- The five-year high for Tax Provisions was $4.3 million in Q4 2023, with the low at -$8.9 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Contineum Therapeutics | 632.27 Mn | 632.27 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -8.89 Mn |
| Dec 31, 2023 | 4.28 Mn |
| Sep 30, 2023 | -118,000.00 |
| Jun 30, 2023 | 729,000.00 |